STAT3 selectively interacts with Smad3 to antagonize TGF-β

Oncogene

Volumn 35, Issue 33, 2016, Pages 4388-4398

  Wang, G ^a,b   Yu, Y ^a   Sun, C ^b,e   Liu, T ^a   Liang, T ^c   Zhan, L ^d   Lin, X ^b   Feng, X H ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Chinese Academy of Sciences   (China)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; RAS PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; SMAD3 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LIVER CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STOMACH EPITHELIUM; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CYTOLOGY; HEK293 CELL LINE; PHYSIOLOGY; TH17 CELL;

CELL DIFFERENTIATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HEK293 CELLS; HUMANS; INTERLEUKIN-6; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; STAT3 TRANSCRIPTION FACTOR; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84949009455     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.446     Document Type: Article

References (50)

1. Derynck R, Miyazono K. The TGF-β Family. Cold Spring Harbor Laboratory Press: New York, NY, USA, 2007, pp. 1-1114.
2. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10: 554-567.
3. Wu MY, Hill CS. TGF-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 2009; 16: 329-343.
4. Massague J. TGFβ in cancer. Cell 2008; 134: 215-230.
5. Ikushima H, Miyazono K. TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-424.
6. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129.
7. Drabsch Y, ten Dijke P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 2012; 31: 553-568.
8. Deheuninck J, Luo K. Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res 2009; 19: 47-57.
9. Wang D, Long J, Dai F, Liang M, Feng X-H, Lin X. BCL6 represses Smad signaling in transforming growth factor-beta resistance. Cell Res 2008; 68: 783-789.
10. Hirai H, Izutsu K, Kurokawa M, Mitani K. Oncogenic mechanisms of Evi-1 protein. Cancer Chemother Pharmacol 2001; 48: S35-S40.
11. Feng X-H, Liang Y-Y, Liang M, Zhai W, Lin X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell 2002; 9: 133-143.
12. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett 2006; 580: 2811-2820.
13. Wrighton KH, Lin X, Feng X-H. Phospho-control of TGF-β superfamily signaling. Cell Res 2009; 19: 8-20.
14. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 1999; 13: 804-816.
15. Feng X-H, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-693.
16. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev Genes Dev 2005; 19: 2783-2810.
17. Labbe E, Silvestri C, Hoodless PA, Wrana JL, Attisano L. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 1998; 2: 109-120.
18. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 1997; 389: 85-89.
19. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 1998; 394: 909-913.
20. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14: 736-746.
21. Ogata H, Chinen T, Yoshida T, Kinjyo I, Takaesu G, Shiraishi H et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006; 25: 2520-2530.
22. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat Med 2005; 11: 845-852.
23. Gunaje JJ, Bhat GJ. Distinct mechanisms of inhibition of interleukin-6-induced Stat3 signaling by TGF-beta and alpha-thrombin in CCL39 cells. Mol Cell Biol Res Commun 2000; 4: 151-157.
24. Walia B, Wang L, Merlin D, Sitaraman SV. TGF-beta down-regulates IL-6 signaling in intestinal epithelial cells: critical role of SMAD-2. FASEB J 2003; 17: 2130-2132.
25. Zauberman A, Lapter S, Zipori D. Smad proteins suppress CCAAT/enhancerbinding protein (C/EBP) beta- and STAT3-mediated transcriptional activation of the haptoglobin promoter. J Biol Chem 2001; 276: 24719-24725.
26. Dunfield LD, Nachtigal MW. Inhibition of the antiproliferative effect of TGFbeta by EGF in primary human ovarian cancer cells. Oncogene 2003; 22: 4745-4751.
27. Luwor RB, Baradaran B, Taylor LE, Iaria J, Nheu TV, Amiry N et al. Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo. Oncogene 2012; 32: 2433-2441.
28. Feng X-H, Zhang Y, Wu R-Y, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-beta. Genes Dev 1998; 12: 2153-2163.
29. Wierenga ATJ, Schuringa JJ, Eggen BJL, Kruijer W, Vellenga E. Downregulation of IL-6-induced STAT3 tyrosine phosphorylation by TGF-β1 is mediated by caspasedependent and -independent processes. Leukemia 2002; 16: 675-682.
30. Campbell JD, Cook G, Robertson SE, Fraser A, Boyd KS, Gracie JA et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. J Immunol 2001; 167: 553-561.
31. Yamamoto T, Matsuda T, Muraguchi A, Miyazono K, Kawabata M. Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells. FEBS Lett 2001; 492: 247-253.
32. Ghosh AK, Yuan W, Mori Y, Sj Chen, Varga J. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factorbeta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001; 276: 11041-11048.
33. Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M et al. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 1999; 284: 479-482.
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
35. Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 2003; 94: 230-234.
36. Ungefroren H, Groth S, Sebens S, Lehnert H, Gieseler F, Fandrich F. Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer 2011; 10: 67.
37. Zheng R, Xiong Q, Zuo B, Jiang S, Li F, Lei M et al. Using RNA interference to identify the different roles of SMAD2 and SMAD3 in NIH/3T3 fibroblast cells. Cell Biochem Funct 2008; 26: 548-556.
38. Huang D, Liu Y, Huang Y, Xie Y, Shen K, Zhang D et al. Mechanical compression upregulates MMP9 through SMAD3 but not SMAD2 modulation in hypertrophic scar fibroblasts. Connect Tissue Res 2014; 55: 391-396.
39. Kim SG, Kim H-A, Jong H-S, Park J-H, Kim NK, Hong SH et al. The endogenous ratio of Smad2 and Smad3 influences the cytostatic function of Smad3. Mol Biol Cell 2005; 16: 4672-4683.
40. Schmierer B, Schuster MK, Shkumatava A, Kuchler K. Activin a signaling induces Smad2, but not Smad3, requiring protein kinase a activity in granulosa cells from the avian ovary. J Biol Chem 2003; 278: 21197-21203.
41. Martinez GJ, Zhang Z, Chung Y, Reynolds JM, Lin X, Jetten AM et al. Smad3 differentially regulates the induction of regulatory and inflammatory T cell differentiation. J Biol Chem 2009; 284: 35283-35286.
42. Martinez GJ, Zhang Z, Reynolds JM, Tanaka S, Chung Y, Liu T et al. Smad2 positively regulates the generation of Th17 cells. J Biol Chem 2010; 285: 29039-29043.
43. Han S-U, Kim H-T, Seong DH, Kim Y-S, Park Y-S, Bang Y-J et al. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 2004; 23: 1333-1341.
44. Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 2004; 351: 552-559.
45. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
46. Okita K, Yamanaka S. Intracellular signaling pathways regulating pluripotency of embryonic stem cells. Curr Stem Cell Res Ther 2006; 1: 103-111.
47. Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 2003; 115: 281-292.
48. Lin X, Duan X, Liang Y-Y, Su Y, Wrighton KH, Long J et al. PPM1A functions as a Smad phosphatase to terminate TGFβ signaling. Cell 2006; 125: 915-928.
49. Dai F, Lin X, Chang C, Feng X-H. Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-beta signaling. Dev Cell 2009; 16: 345-357.
50. Lin X, Liang Y-Y, Sun B, Liang M, Shi Y, Brunicardi FC et al. Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription. Mol Cell Biol 2003; 23: 9081-9093.